Oct 28, 2022

  • Corporate

Purchase of Land for Business in Ukima

  • Concluded a purchase agreement for adjacent land to expand the Ukima Site
  • Strengthen the pharmaceutical technology function to accelerate RED SHIFT and promote environmental initiatives for the sustainable development of both Chugai and society

TOKYO, Oct 28, 2022 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that it concluded a sale and purchase agreement today with Fuji Amide Chemical Co., Ltd. to purchase land in Kita-ku from Fuji Amid. The property is bordering the west side of Chugai's Ukima Site.

The Ukima Site is a hub of Chugai’s pharmaceutical technology function, which is responsible for manufacturing process research. The site also includes the Ukima Plant of Chugai’s manufacturing subsidiary, Chugai Pharma Manufacturing Co., Ltd. Chugai plans to utilize the new land to strengthen the pharmaceutical function. It is also expected that the expansion of the site will facilitate the progress of environmental initiatives across the site. By means of measures including the renewal of buildings and facilities, hydrofluorocarbon-free technologies and energy conservation, Chugai will pursue the elimination of hydrofluorocarbons and the reduction of CO2 emission and energy consumption as stated in our Mid-Term Environmental Goals 2030.

“The acquisition of the land is part of RED SHIFT*, a key driver of our growth strategy TOP I 2030. In order to bring new drug candidates from research to clinical development, it is extremely important to quickly establish manufacturing methods as pharmaceuticals. By strengthening the pharmaceutical technology function and the foundation to rapidly initiate clinical development, we aim to deliver innovative drugs to patients as soon as possible,” said Chugai’s President and CEO, Dr. Osamu Okuda. “We will also accelerate environmental measures at the Ukima Site. Manufacturing and research functions play a key role to achieve the high goals in the Mid-Term Environmental Goals 2030. We will continue our efforts to reduce environmental burdens for the sustainable development of both Chugai and society.”

*RED SHIFT: RED stands for Research & Early Development, and RED functions correspond to the initial development stages of research, early clinical development, and pharmaceutical technology functions. By focusing resources and expanding investment in RED functions, Chugai aims to enhance capabilities from drug discovery, the source of its value creation, to translational research for acquiring PoC, and to increase R&D outputs.

Contents of the property purchased

Location: 5 -8 -18 Ukima, Kita-ku, Tokyo
Land area: 14,107.12m2

Overview of Fuji Amide

Company name: Fuji Amide Chemical Co., Ltd.
Address: 5 -8 -18 Ukima, Kita-ku, Tokyo
Representative: President, Yoshiaki Okunaka
Established: June 17, 1972
Capital: 30 million yen
Sales: 758 million yen (Fiscal Year ended March 2022)


Transfer of property: September 2025 (planned)


  • For Media
  • Chugai Pharmaceutical Co., Ltd.
  • Media Relations Group, Corporate Communications Dept.,
  • Tomoko Shimizu
  • Tel: +81-3-3273-0881
  • E-mail: pr@chugai-pharm.co.jp
  • For Investors
  • Chugai Pharmaceutical Co., Ltd.
  • Investor Relations Group, Corporate Communications Dept.,
  • Takayuki Sakurai
  • Tel: +81-3-3273-0554
  • E-mail: ir@chugai-pharm.co.jp
  • Like
  • Post
  • LINE it!
  • E-mail
Back to top